BMS and Dr Reddy’s settle Revlimid suit with generics licence
22-09-2020
Gilead to buy Immunomedics for $21bn
14-09-2020
nitpicker / Shutterstock.com
Bristol Myers Squibb (BMS) has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BMS, Bristol Myers Squibb, MyoKardia, M&A, mergers and acquisitions, cardiovascular, heart disease, biotech, mavacamten
